Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients with localized hormone-dependent breast cancer. 200 patients will be included in the study. Each patient will be followed for one day.

Trial Details

NCT ID
NCT04740697
Phase
NA
Sponsor
Institut Claudius Regaud
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
Locations (sample)
  • Toulouse, France|43.60426,1.44367

Key Eligibility Criteria

  • Age ≥ 18 years at entry into the study.
  • Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
  • Patients treated with tamoxifen for a maximum of 1 to 3 years.
  • Patient affiliated with a Social Security system in France.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →